vimarsana.com

Page 13 - பத்திரங்கள் ஒன்றுபட்டது மாநிலங்களில் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

[HK]汇森家居:部分行使超额配股权、稳定价格行动及稳定价格期结束- CFi CN 中财网

[HK]汇森家居:部分行使超额配股权、稳定价格行动及稳定价格期结束- CFi CN 中财网
cfi.net.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cfi.net.cn Daily Mail and Mail on Sunday newspapers.

FibroGen Down; FDA Extends Review Period for Roxadustat

Provided by Dow Jones By Michael Dabaie FibroGen Inc. shares were down 14% to $37.66 in late morning trading. The company said after the market close Friday that the Food and Drug Administration extended the review period of the new drug application for roxadustat for the treatment of anemia of chronic kidney disease by three months. The updated Prescription Drug User Fee Act action date is March 20, 2021, the company said. FibroGen said the FDA is close to finalizing its review of the NDA. FibroGen is submitting additional analyses of existing roxadustat clinical data, which require an extension of the original PDUFA date.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.